by MM360 Staff | Jul 18, 2018 | Myeloma News
Celgene Amends Phase 2 Multiple Myeloma Study with a dose increase for bb2121 Celgene (CELG) has amended the protocol for the phase 2 KarMMa study: Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma. Celgene is developing...
by MM360 Staff | Jul 18, 2018 | Myeloma News
A University of Southern California cancer physicist is on a quest to develop a mapping tool for cancer, including Multiple Myeloma that is as easy to use as the Google Maps or Waze mobile apps. The U.S. Food and Drug Administration recently announced a collaboration...
by MM360 Staff | Jul 17, 2018 | Myeloma News
The treatment of multiple myeloma has changed dramatically over the past 15 years. Patients are living longer. In patients who are newly diagnosed, triple therapy has resulted in high response rates and deeper, longer lasting responses. However, due to the...
by MM360 Staff | Jul 13, 2018 | EHA 2018, Featured News, Videos
Once-Weekly Vs Twice-Weekly Carfilzomib Dosing Plus Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Randomized Phase 3 Study A.R.R.O.W. Authors: Maria-Victoria Mateos , Philippe Moreau , James R. Berenson , Katja Weisel ,...
by MM360 Staff | Jul 12, 2018 | EHA 2018, Featured News, Videos
OPTIMISMM: Phase 3 Trial of Pomalidomide, Bortezomib, and Low‐Dose Dexamethasone vs Bortezomib and Low-Dose Dexamethasone in Lenalidomide-Exposed Patients with Relapsed/Refractory Multiple Myeloma Author(s): Paul Richardson , Albert Oriol Rocafiguera , Meral Beksac ,...
